Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hyperion Therapeutics has completed patient enrollment in its Phase I/II clinical trial to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 versus Buphenyl in patients with urea cycle disorders. The company plans to announce top-line results in the fourth quarter of 2008.
Subscribe to our email newsletter
HPN-100 is a pro-drug of phenylbutryrate and a pre-pro-drug of phenylacetic acid, the active moiety of Buphenyl, the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders – carbamylphosphate synthetase, ornithine transcarbamylase, and argininosuccinic acid synthetase.
Bruce Scharschmidt, chief medical officer of Hyperion, said: “Completing enrollment in this Phase I/II study is an important milestone in our development program. This represents the first trial of HPN-100 in patients with urea cycle disorders and the results will be important in assessing its potential to improve care for these patients.”